guest ::
| Home > Publications database > Putaminal y ‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease > print |
| Home > Publications database > Putaminal y ‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease > print |
| 001 | 893096 | ||
| 005 | 20211130111106.0 | ||
| 024 | 7 | _ | |a 10.1002/mds.28674 |2 doi |
| 024 | 7 | _ | |a 0885-3185 |2 ISSN |
| 024 | 7 | _ | |a 1531-8257 |2 ISSN |
| 024 | 7 | _ | |a 2128/28785 |2 Handle |
| 024 | 7 | _ | |a altmetric:107241471 |2 altmetric |
| 024 | 7 | _ | |a pmid:34096652 |2 pmid |
| 024 | 7 | _ | |a WOS:000658342200001 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-02555 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Seger, Aline |0 P:(DE-Juel1)184882 |b 0 |
| 245 | _ | _ | |a Putaminal y ‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease |
| 260 | _ | _ | |a New York, NY |c 2021 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1634192128_4066 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a BackgroundMotor response to dopaminergic therapy is a characteristic of patients with Parkinson's disease (PD). Whether nondopaminergic neurotransmitters contribute to treatment response is uncertain.ObjectivesThe aim of this study is to determine whether putaminal y-aminobutyric acid (GABA) levels are associated with dopaminergic motor response.MethodsWe assessed putaminal GABA levels in 19 PD patients and 13 healthy controls (HCs) utilizing ultra-high field proton magnetic resonance spectroscopy. Motor performance was evaluated using the Movement Disorder Society—Unified Parkinson's Disease Rating Scale, Part III, in the ON and OFF states. Statistical analysis comprised group comparisons, correlation analysis, and multiple linear regression.ResultsIn PD, GABA levels were significantly higher compared to HCs (1.50 ± 0.26 mM vs. 1.26 ± 0.31 mM, P = 0.022). Furthermore, GABA levels were independent predictors of absolute and relative dopaminergic treatment response.ConclusionsOur findings indicate that elevated putaminal GABA levels are associated with worse dopaminergic response in PD, emphasizing the essential role of nondopaminergic neurotransmitters in motor response. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society |
| 536 | _ | _ | |a 525 - Decoding Brain Organization and Dysfunction (POF4-525) |0 G:(DE-HGF)POF4-525 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Farrher, Ezequiel |0 P:(DE-Juel1)138244 |b 1 |
| 700 | 1 | _ | |a Doppler, Christopher E. J. |0 P:(DE-Juel1)161350 |b 2 |
| 700 | 1 | _ | |a Gogishvili, Ana |0 P:(DE-Juel1)178065 |b 3 |
| 700 | 1 | _ | |a Worthoff, Wieland A. |0 P:(DE-Juel1)156200 |b 4 |
| 700 | 1 | _ | |a Filss, Christian P. |0 P:(DE-Juel1)141877 |b 5 |
| 700 | 1 | _ | |a Barbe, Michael T. |0 P:(DE-Juel1)131613 |b 6 |
| 700 | 1 | _ | |a Holtbernd, Florian |0 P:(DE-Juel1)188521 |b 7 |
| 700 | 1 | _ | |a Shah, N. Jon |0 P:(DE-Juel1)131794 |b 8 |
| 700 | 1 | _ | |a Fink, Gereon R. |0 P:(DE-Juel1)131720 |b 9 |u fzj |
| 700 | 1 | _ | |a Sommerauer, Michael |0 P:(DE-Juel1)179044 |b 10 |e Corresponding author |
| 773 | _ | _ | |a 10.1002/mds.28674 |g p. mds.28674 |0 PERI:(DE-600)2041249-6 |n 9 |p 2187-2192 |t Movement disorders |v 36 |y 2021 |x 1531-8257 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/893096/files/mds.28674.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:893096 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)184882 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)138244 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)161350 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)178065 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)156200 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)141877 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)188521 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)131794 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)131720 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)179044 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-573 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-500 |4 G:(DE-HGF)POF |v Neuroimaging |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-30 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-30 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOVEMENT DISORD : 2019 |d 2021-01-30 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-01-30 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-30 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-30 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-30 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOVEMENT DISORD : 2019 |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-30 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-01-30 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-30 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 1 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-11-20170113 |k INM-11 |l Jara-Institut Quantum Information |x 2 |
| 920 | 1 | _ | |0 I:(DE-Juel1)VDB1046 |k JARA-BRAIN |l Jülich-Aachen Research Alliance - Translational Brain Medicine |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-11-20170113 |
| 980 | _ | _ | |a I:(DE-Juel1)VDB1046 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|